BioVersys AG, Basel, Switzerland
Biozentrum, University of Basel, Basel, Switzerland.
mBio. 2019 Jul 16;10(4):e01083-19. doi: 10.1128/mBio.01083-19.
Nosocomial infections with are a global problem in intensive care units with high mortality rates. Increasing resistance to first- and second-line antibiotics has forced the use of colistin as last-resort treatment, and increasing development of colistin resistance in has been reported. We evaluated the transcriptional regulator PmrA as potential drug target to restore colistin efficacy in Deletion of restored colistin susceptibility in 10 of the 12 extensively drug-resistant clinical isolates studied, indicating the importance of PmrA in the drug resistance phenotype. However, two strains remained highly resistant, indicating that PmrA-mediated overexpression of the phosphoethanolamine (PetN) transferase PmrC is not the exclusive colistin resistance mechanism in A detailed genetic characterization revealed a new colistin resistance mechanism mediated by genetic integration of the insertion element IS upstream of the PmrC homolog EptA (93% identity), leading to its overexpression. We found that was ubiquitously present in clinical strains belonging to the international clone 2, and IS integration upstream of was required to mediate the colistin-resistant phenotype. In addition, we found a duplicated IS- cassette in one isolate, indicating that this colistin resistance determinant may be embedded in a mobile genetic element. Our data disprove PmrA as a drug target for adjuvant therapy but highlight the importance of PetN transferase-mediated colistin resistance in clinical strains. We suggest that direct targeting of the homologous PetN transferases PmrC/EptA may have the potential to overcome colistin resistance in The discovery of antibiotics revolutionized modern medicine and enabled us to cure previously deadly bacterial infections. However, a progressive increase in antibiotic resistance rates is a major and global threat for our health care system. Colistin represents one of our last-resort antibiotics that is still active against most Gram-negative bacterial pathogens, but increasing resistance is reported worldwide, in particular due to the plasmid-encoded protein MCR-1 present in pathogens such as and Here, we showed that colistin resistance in , a top-priority pathogen causing deadly nosocomial infections, is mediated through different avenues that result in increased activity of homologous phosphoethanolamine (PetN) transferases. Considering that MCR-1 is also a PetN transferase, our findings indicate that PetN transferases might be the Achilles heel of superbugs and that direct targeting of them may have the potential to preserve the activity of polymyxin antibiotics.
医院获得性感染是重症监护病房中一个全球性的问题,死亡率很高。对一线和二线抗生素的耐药性不断增加,迫使人们使用多粘菌素作为最后的治疗手段,而 中多粘菌素耐药性的不断发展也有报道。我们评估了转录调节因子 PmrA 作为潜在的药物靶点,以恢复 对多粘菌素的敏感性。缺失 恢复了 12 株广泛耐药 临床分离株中的 10 株对多粘菌素的敏感性,表明 PmrA 在耐药表型中很重要。然而,有两个菌株仍然高度耐药,这表明 PmrA 介导的磷酸乙醇胺(PetN)转移酶 PmrC 的过度表达并不是 对多粘菌素耐药的唯一机制。详细的遗传特征表明,一种新的多粘菌素耐药机制是由插入元件 IS 在 PmrC 同源物 EptA 上游的基因整合介导的(93%的同一性),导致其过度表达。我们发现 在属于国际克隆 2 的临床菌株中普遍存在,并且 在 IS 整合上游是介导多粘菌素耐药表型所必需的。此外,我们在一个分离株中发现了一个重复的 IS-盒,表明该多粘菌素耐药决定因素可能嵌入在一个可移动遗传元件中。我们的数据否定了 PmrA 作为辅助治疗的药物靶点,但强调了 PetN 转移酶介导的多粘菌素耐药在临床菌株中的重要性。我们建议直接针对同源的 PetN 转移酶 PmrC/EptA 可能有潜力克服 中的多粘菌素耐药性。抗生素的发现彻底改变了现代医学,使我们能够治愈以前致命的细菌感染。然而,抗生素耐药率的不断上升是我们医疗保健系统的一个主要的全球性威胁。多粘菌素是我们对抗大多数革兰氏阴性细菌病原体仍然有效的最后一种抗生素之一,但世界各地都有耐药性增加的报道,特别是由于在病原体如 和 中存在质粒编码的 MCR-1。在这里,我们表明,在 中,一种导致致命医院获得性感染的首要病原体,多粘菌素耐药是通过不同途径介导的,导致同源磷酸乙醇胺(PetN)转移酶活性增加。考虑到 MCR-1 也是一种 PetN 转移酶,我们的发现表明 PetN 转移酶可能是超级细菌的阿喀琉斯之踵,直接针对它们可能有潜力保护多粘菌素类抗生素的活性。